IR Notice
Dear Investors,
This is John Rim CEO of Samsung Biologics
This year marks the 10th anniversary of Samsung Biologics' business.
In 2011, when other global companies hesitated to invest in new businesses, Samsung invested in a decisive manner to preempt opportunities. Since the we have continuously innovated in facilities construction and process opatimization. Based on Samsung group's heritage of "Quality Management," Samsung Biologics reached the top-tier in the biopharmaceutical industry in a short period of time, while providing the highest quality along with fast and flexible services to our clients.
- Employees
- 3,400 +
- Total Capacity
- 620KL include P4(~end of 2022)
- Regulatory Approvals
- 85
- Cumulative Orders
- CMO 57 products
- Cumulative Orders
- CDO 68 products
US R&D Center
Due to increase in plant 3 utilization, both revenue and operating profit increased in 2021 1Q
Based on Plant 3 utilization ramp-up, Samsung Biologics recorded 260.8 billion won is sales, a 53.6 billion won increase compared to the previous year. Operating profit was recorded at 74.3 billion won due to stable operations in plants 1 and 2, and the rapid fill in Plant 3 capacity.
In 2021, plants 1 and 2 will be fully utilized with stable operations, and Plant 3 will be near-full operationally. This will lead to even greater growth in sales and operating profit compared to the previous year.
Due to the COVID-19 pandemic, market trends hav changed with a strong demand for clinical and commercial production capacity for COVID-19 treatments and vaccines. Additionally, global biopharmaceutical companies have now begun diversifying their SCM strategies more than ever.
Responding to these trends and in consideration of internal orders intake, we announced the expansion of Plant 4 in the secoun half of last year. Currently, Plant 4, with a total expected capacity of 256,000L is on track to be partially operational by the end of 2022. We are also actively focused on Plant 4 pre-sales as we continue to ramp up construction activities.
By operating plants 1, 2 and 3, we've accumulated multiple track records for our production capabilities to flexibley meet every demand from preclinical to commercial products. Specifically to address the COVID-19 pandemic, we developed the Live Virtual Toursolution in advance to support client due diligence activities and global regulatory inspections. With all these abilities along with our unrelenting focus on our mission to improve lives as distilled in our recentrly unveiled "Driven. For Life" slogan, we have high expectations for Plant 4 pre-sales and the continuation of our business expansion.
In the past 10 years, Samsung Biologics focused on stabilizing its business and expanding production capacity. Going forward, we will focus on not only expanding capacity, but also on diversifying our business portfolio by expanding our global base and capabilities in the next 10 years.
We will become a fully integrated global top-tier biopharmaceutical company.
We ask for your continued trust and support, and wish you and your family good health and happiness.
Thank you.
Sincerely, John Rim President and CEO, Samsung Biologics
Dear Investors,
This is John Rim CEO of Samsung Biologics
This year marks the 10th anniversary of Samsung Biologics' business.
In 2011, when other global companies hesitated to invest in new businesses, Samsung invested in a decisive manner to preempt opportunities. Since the we have continuously innovated in facilities construction and process opatimization. Based on Samsung group's heritage of "Quality Management," Samsung Biologics reached the top-tier in the biopharmaceutical industry in a short period of time, while providing the highest quality along with fast and flexible services to our clients.
- Employees
- 3,400 +
- Total Capacity
- 620KL include P4(~end of 2022)
- Regulatory Approvals
- 85
- Cumulative Orders
- CMO 57 products
- Cumulative Orders
- CDO 68 products
US R&D Center
Due to increase in plant 3 utilization, both revenue and operating profit increased in 2021 1Q
Based on Plant 3 utilization ramp-up, Samsung Biologics recorded 260.8 billion won is sales, a 53.6 billion won increase compared to the previous year. Operating profit was recorded at 74.3 billion won due to stable operations in plants 1 and 2, and the rapid fill in Plant 3 capacity.
In 2021, plants 1 and 2 will be fully utilized with stable operations, and Plant 3 will be near-full operationally. This will lead to even greater growth in sales and operating profit compared to the previous year.
Due to the COVID-19 pandemic, market trends hav changed with a strong demand for clinical and commercial production capacity for COVID-19 treatments and vaccines. Additionally, global biopharmaceutical companies have now begun diversifying their SCM strategies more than ever.
Responding to these trends and in consideration of internal orders intake, we announced the expansion of Plant 4 in the secoun half of last year. Currently, Plant 4, with a total expected capacity of 256,000L is on track to be partially operational by the end of 2022. We are also actively focused on Plant 4 pre-sales as we continue to ramp up construction activities.
By operating plants 1, 2 and 3, we've accumulated multiple track records for our production capabilities to flexibley meet every demand from preclinical to commercial products. Specifically to address the COVID-19 pandemic, we developed the Live Virtual Toursolution in advance to support client due diligence activities and global regulatory inspections. With all these abilities along with our unrelenting focus on our mission to improve lives as distilled in our recentrly unveiled "Driven. For Life" slogan, we have high expectations for Plant 4 pre-sales and the continuation of our business expansion.
In the past 10 years, Samsung Biologics focused on stabilizing its business and expanding production capacity. Going forward, we will focus on not only expanding capacity, but also on diversifying our business portfolio by expanding our global base and capabilities in the next 10 years.
We will become a fully integrated global top-tier biopharmaceutical company.
We ask for your continued trust and support, and wish you and your family good health and happiness.
Thank you.
Sincerely, John Rim President and CEO, Samsung Biologics